Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Rare disease families find roadmap to drug development at bootcamps
Rare disease families are increasingly driving research efforts to find treatments for their children. Ultragenyx's Rare Bootcamp gives advocates a roadmap for navigating drug development.
There's a New Rare-Earth Stock. Here's What Makes It Stand Out.
Tuesday, Rare Earth Americas priced its IPO at $19 per share.
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect
Ultragenyx posts a wider-than-expected Q1 loss as Crysvita sales fall on seasonal effects, while Evkeeza and Dojolvi revenue growth partially offset declines.
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript
Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $1.84 per share versus the Zacks Consensus Estimate of a loss of $1.55. This compares to a loss of $1.57 per share a year ago.
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx Pharmaceutical: The Market Is Overlooking 2026 Catalysts
Ultragenyx Pharmaceutical remains a speculative conviction hold (3/5) as its commercial base funds a robust late-stage rare disease pipeline. Multiple pivotal catalysts in 2026–2027, including GTX-102, DTX401, and UX111, could drive significant revenue growth and shift sentiment. Conservative U.S.-only modeling suggests $1.5B–$2.4B peak annual revenue potential from late-stage programs, with Street estimates supporting multi-bagger upside.
RARE Rises as FDA Accepts Resubmitted BLA for Sanfilippo Syndrome
Ultragenyx Pharmaceutical jumps 5% as the FDA accepts UX111 BLA resubmission, setting up a September 2026 decision for a potential first treatment for MPS IIIA.
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND
RARE's IND for UX016, a novel sialic acid prodrug targeting GNEM, a rare muscle disease, gets accepted by the FDA. The first-in-human study is slated for H2'26.
